Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (12983)	10/6/2003 2:45:50 AM
From: Cal Gary	Respond to of 14101

Nice company: Board of Directors The board of directors oversees the affairs of the Canadian Arthritis Network, including its research programs, resource allocation and budgeting, conflict-of-interest protocols, intellectual-property management, technology transfer and commercialization, as well as networking and communications. The Board reports to the NCE steering committee on these matters and about turnover in board membership. Click on a member's name to find out more information. Research and clinical expertise: Dr. Jane Aubin (professor and chair of the Department of Anatomy and Cell Biology at the University of Toronto), the nominated representative for CAN members, chair of the research management committee and scientific co-director. Dr. Robin Poole (Director, Joint Diseases Laboratory, Shriners Hospital for Children), scientific co-director. Academic community expertise: Dr. Robin Armstrong, Past President, University of New Brunswick. Dr. Chris Triggle, Associate Dean of Research (Medicine), University of Calgary. Pharmaceutical and biotech industry expertise: Mike Cloutier, past-President and CEO of Pharmacia Canada. Dr. Tony Cruz, co-founder of Transition Therapeutics Inc., and HDM Diagnostics Inc.; senior scientist at Samuel Lunenfeld Research Institute; professor, University of Toronto. Jeff Davis, general manager of Procter & Gamble Pharmaceuticals, Canada. Chris Nelson, President, Canadian Arthritis Network. Government representation: The Honourable Pat Carney, Senator for British Columbia. Business community Representing business sectors unrelated to biotech and pharmaceutical manufacturing are: Sydney Jackson, past-Chair and CEO of Manufacturers Life and past-Chair of The Arthritis Society's Board of Directors. Mr. Jackson has graciously accepted to be the first Chair of the Canadian Arthritis Network's Board of Directors. Bill Woloshyn, Senior Partner of McMillan Binch Arthritis community representation: Denis Morrice, President and CEO of The Arthritis Society. Ron Simpson, Executive Committee member, The Arthritis Society. Networks of Centres of Excellence Ms. Chantal Abou-Debs, NCE Program Officer (a non-voting member who liases with the Networks of Centres of Excellence directorate). arthritisnetwork.ca

To: Cal Gary who wrote (12983)	10/6/2003 8:43:53 AM
From: gg cox	Read Replies (1) \| Respond to of 14101

Hi, Cal Gary, I couldn't find the article in 50 plus on the web so I typed it from the issue, here it is again.. "Topical treatment for osteoarthritis gets the nod For Canadians suffering with osteoarthritis of the knee, a new weapon has been developed in the fight against the daily aches, pains, stiffness and sometimes debilitating effects associated with the disease. Pensaid is a topical non-steroidal anti-inflammatory drug (NSAID) recently approved by Health Canada, developed as an alternative to oral NSAIDs for treatment of osteoarthritis of the knee. Pennsaid eliminates the risk of the side effects associated with oral NSAIDs, such as gastrointestinal bleeding, and kidney and liver disease. The new topically applied treatment may be just the drug OA sufferes have been waiting for. Pennsaid works by delivering diclofenac sodium, an anti-arthritic, through the skin directly to the site of pain. Side effects of Pennsaid can include dry or irritated skin. Ask your doctor if Pennsaid is a good choice for you." gg As I said before, it would be nice to see an article similar to this in AARP.